Form 4: Bristol-Myers Squibb Director Acquires Deferred Share Units

Director Michael R. McMullen acquired deferred share units convertible to common stock in Bristol-Myers Squibb on March 31, 2025.

Summary

• On March 31, 2025, Michael R. McMullen, a director of Bristol-Myers Squibb, acquired 512.379 deferred share units.
• These units are convertible into shares of common stock upon settlement, which occurs when McMullen ceases to be a director or at a previously specified future date.
• The price of the deferred share units was $60.99.
• Following the transaction, McMullen directly owns 8,339.083 shares of common stock, which includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects a director increasing their stake in the company, which can be interpreted as a sign of confidence. However, it's a routine transaction related to compensation.

Future Outlook

The deferred share units will be converted into common stock upon settlement when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, such as directors, offering insights into their confidence in the company's prospects.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment as it reflects a director's increased investment in the company.

Key Dates

Keywords

Form 4, Director, Deferred Share Units, Michael R. McMullen, Bristol-Myers Squibb, BMY, Beneficial Ownership